retatrutide on the market ⚠️ Before you consider using retatrutide, know facts. has not completed the FDA approval process, there is no official assessment confirming its safety or quality. The risks are real: 🚫 Retatrutide (LY-3437943) Market Analysis, 2033:

The Cherry on Top The retatrutide readout is just one of three major trials that Lilly has read out in recent months, all of them successful

The published literature here is unusually deep: STEP, SUSTAIN, SURPASS, SURMOUNT, and SELECT phase 3 trial programmes collectively span tens of thousands of subjects across glycaemic, body-weight, hepatic-fat, renal, and cardiovascular endpoints

The drugs can have unsavory side effects, most frequently nausea

Multivariate logistic regression was performed to develop models that predict MAFLD and SF using TE as the reference standard

This contributes to the broader evidence base for the medicine's safety profile and is an important part of how medicines are evaluated before licensing